Received Jun 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 2 | 054C21A | IM |
Hyperlipidemia, continues to increase and not lower; Body inflammation; Weight gain; This spontaneous case was reported by a consumer and describes the occurrence of HYPERLIPIDAEMIA (Hyperlipidemia, continues to increase and not lower), INFLAMMATION (Body inflammation) and WEIGHT INCREASED (Weight gain) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 054C21A and 054C21A) for COVID-19 prophylaxis. No Medical History information was reported. On 28-May-2021 at 10:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) 1 dosage form. On 25-Jun-2021 at 11:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) dosage was changed to 1 dosage form. On 01-Jun-2022, the patient experienced HYPERLIPIDAEMIA (Hyperlipidemia, continues to increase and not lower), INFLAMMATION (Body inflammation) and WEIGHT INCREASED (Weight gain). The patient was treated with Fluvastatin sodium (oral use) at a dose of 20 milligram once a day. At the time of the report, HYPERLIPIDAEMIA (Hyperlipidemia, continues to increase and not lower), INFLAMMATION (Body inflammation) and WEIGHT INCREASED (Weight gain) had not resolved. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Jun-2022, Weight: Weight gain. Concomitant medication use information was not provided by reporter.
Test Date: 20220601; Test Name: Weight; Result Unstructured Data: Weight gain